FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204393409> ?p ?o ?g. }

• W3204393409 endingPage "5322" @default.
• W3204393409 startingPage "5312" @default.
• W3204393409 abstract "Abstract Infections are a known complication of chimeric antigen receptor (CAR) T-cell therapy with data largely emerging from CD19 CAR T-cell targeting. As CAR T-cell therapy continues to evolve, infection risks and management thereof will become increasingly important to optimize outcomes across the spectrum of antigens and disease targeted. We retrospectively characterized infectious complications occurring in 162 children and adults treated among 5 phase 1 CAR T-cell clinical trials. Trials included targeting of CD19, CD22, disialoganglioside (GD2) or B-cell maturation antigen (BCMA). Fifty-three patients (32.7%) had 76 infections between lymphocyte depleting (LD) chemotherapy and day 30 (D30); with the majority of infections (61, 80.3%) occurring between day 0 (D0) and D30. By trial, the highest proportion of infections was seen with CD22 CAR T cells (n = 23/53; 43.4%), followed by BCMA CAR T cells (n = 9/24; 37.5%). By disease, patients with multiple myeloma had the highest proportion of infections (9/24; 37.5%) followed by acute lymphoblastic leukemia (36/102; 35.3%). Grade 4 infections were rare (n = 4; 2.5%). Between D0 and D30, bacteremia and bacterial site infections were the most common infection type. In univariate analysis, increasing prior lines of therapy, recent infection within 100 days of LD chemotherapy, corticosteroid or tocilizumab use, and fever and neutropenia were associated with a higher risk of infection. In a multivariable analysis, only prior lines of therapy and recent infection were associated with higher risk of infection. In conclusion, we provide a broad overview of infection risk within the first 30 days post infusion across a host of multiple targets and diseases, elucidating both unique characteristics and commonalities highlighting aspects important to improving patient outcomes." @default.
• W3204393409 created "2021-10-11" @default.
• W3204393409 creator A5007115015 @default.
• W3204393409 creator A5017207916 @default.
• W3204393409 creator A5021388942 @default.
• W3204393409 creator A5023659191 @default.
• W3204393409 creator A5029895164 @default.
• W3204393409 creator A5030044268 @default.
• W3204393409 creator A5035242151 @default.
• W3204393409 creator A5035585356 @default.
• W3204393409 creator A5036697217 @default.
• W3204393409 creator A5044239219 @default.
• W3204393409 creator A5066864388 @default.
• W3204393409 creator A5069947337 @default.
• W3204393409 creator A5070693731 @default.
• W3204393409 creator A5076065961 @default.
• W3204393409 creator A5087779758 @default.
• W3204393409 date "2021-12-08" @default.
• W3204393409 modified "2023-10-10" @default.
• W3204393409 title "Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days" @default.
• W3204393409 cites W1973617793 @default.
• W3204393409 cites W2082708772 @default.
• W3204393409 cites W2129702476 @default.
• W3204393409 cites W2153147430 @default.
• W3204393409 cites W2471662063 @default.
• W3204393409 cites W2754562068 @default.
• W3204393409 cites W2766745670 @default.
• W3204393409 cites W2768823259 @default.
• W3204393409 cites W2793787928 @default.
• W3204393409 cites W2793826339 @default.
• W3204393409 cites W2807637103 @default.
• W3204393409 cites W2808166290 @default.
• W3204393409 cites W2901262057 @default.
• W3204393409 cites W2905654445 @default.
• W3204393409 cites W2982266707 @default.
• W3204393409 cites W2998859344 @default.
• W3204393409 cites W3015514251 @default.
• W3204393409 cites W3016233874 @default.
• W3204393409 cites W3031492407 @default.
• W3204393409 cites W3037830886 @default.
• W3204393409 cites W3046970338 @default.
• W3204393409 cites W3112902030 @default.
• W3204393409 cites W3120738879 @default.
• W3204393409 cites W3138004978 @default.
• W3204393409 cites W3168769953 @default.
• W3204393409 cites W3184767083 @default.
• W3204393409 doi "https://doi.org/10.1182/bloodadvances.2021004896" @default.
• W3204393409 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34619768" @default.
• W3204393409 hasPublicationYear "2021" @default.
• W3204393409 type Work @default.
• W3204393409 sameAs 3204393409 @default.
• W3204393409 citedByCount "20" @default.
• W3204393409 countsByYear W32043934092022 @default.
• W3204393409 countsByYear W32043934092023 @default.
• W3204393409 crossrefType "journal-article" @default.
• W3204393409 hasAuthorship W3204393409A5007115015 @default.
• W3204393409 hasAuthorship W3204393409A5017207916 @default.
• W3204393409 hasAuthorship W3204393409A5021388942 @default.
• W3204393409 hasAuthorship W3204393409A5023659191 @default.
• W3204393409 hasAuthorship W3204393409A5029895164 @default.
• W3204393409 hasAuthorship W3204393409A5030044268 @default.
• W3204393409 hasAuthorship W3204393409A5035242151 @default.
• W3204393409 hasAuthorship W3204393409A5035585356 @default.
• W3204393409 hasAuthorship W3204393409A5036697217 @default.
• W3204393409 hasAuthorship W3204393409A5044239219 @default.
• W3204393409 hasAuthorship W3204393409A5066864388 @default.
• W3204393409 hasAuthorship W3204393409A5069947337 @default.
• W3204393409 hasAuthorship W3204393409A5070693731 @default.
• W3204393409 hasAuthorship W3204393409A5076065961 @default.
• W3204393409 hasAuthorship W3204393409A5087779758 @default.
• W3204393409 hasBestOaLocation W32043934091 @default.
• W3204393409 hasConcept C126322002 @default.
• W3204393409 hasConcept C147483822 @default.
• W3204393409 hasConcept C203014093 @default.
• W3204393409 hasConcept C2776090121 @default.
• W3204393409 hasConcept C2776694085 @default.
• W3204393409 hasConcept C2777063308 @default.
• W3204393409 hasConcept C3875195 @default.
• W3204393409 hasConcept C71924100 @default.
• W3204393409 hasConcept C8891405 @default.
• W3204393409 hasConceptScore W3204393409C126322002 @default.
• W3204393409 hasConceptScore W3204393409C147483822 @default.
• W3204393409 hasConceptScore W3204393409C203014093 @default.
• W3204393409 hasConceptScore W3204393409C2776090121 @default.
• W3204393409 hasConceptScore W3204393409C2776694085 @default.
• W3204393409 hasConceptScore W3204393409C2777063308 @default.
• W3204393409 hasConceptScore W3204393409C3875195 @default.
• W3204393409 hasConceptScore W3204393409C71924100 @default.
• W3204393409 hasConceptScore W3204393409C8891405 @default.
• W3204393409 hasIssue "23" @default.
• W3204393409 hasLocation W32043934091 @default.
• W3204393409 hasLocation W32043934092 @default.
• W3204393409 hasLocation W32043934093 @default.
• W3204393409 hasOpenAccess W3204393409 @default.
• W3204393409 hasPrimaryLocation W32043934091 @default.
• W3204393409 hasRelatedWork W2064357373 @default.
• W3204393409 hasRelatedWork W2316813997 @default.
• W3204393409 hasRelatedWork W2326367365 @default.

• next